Group 1 - The establishment of the "Binhai Artificial Intelligence Medical Device Innovation Industry Alliance" aims to integrate innovative resources and promote deep integration of AI and medical device industries, creating a collaborative and open innovation ecosystem [1] - The "Binhai G3LAB High-end Medical Device Innovation Platform" has been launched to gather policy, capital, and industry chain resources, focusing on three cutting-edge areas: structural heart disease, neurointervention, and endoscopic treatment [1] - Experts highlight that AI medical device products are in the early stages of development, with a need for improved R&D innovation and regulatory capabilities, addressing challenges across the industry chain is a common challenge faced by the industry [1] Group 2 - The R&D cycle for high-end medical devices typically lasts 5-8 years, and the platform's support will alleviate financial pressures and regulatory challenges for innovative companies, particularly in the "AI + medical" integration technology [2] - The future development of AI medical devices requires collaboration among industry, academia, research, and medical sectors to integrate clinical needs with engineering innovation, establishing compliant and efficient data platforms to accelerate technology transfer and application [2] - AI is reshaping the paradigm of device R&D, enhancing innovation and redefining products, with companies leveraging AI to mine data, identify technological gaps, and develop innovative solutions that improve diagnostic accuracy [2] Group 3 - AI's application in cardiovascular diagnosis and treatment has gained attention, with significant advancements in recent years due to progress in data, algorithms, and computing power [3] - The focus of AI applications has primarily been on cardiovascular imaging and single-modal imaging research, while multi-modal imaging and generative AI represent the forefront of cardiovascular imaging research [3]